Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Carvedilol;   Drug: Metoprolol
Sponsor:   Federico II University
Recruiting - verified June 2016

Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Bassett Healthcare;   Baylor University
Not yet recruiting - verified June 2016

Interest of CARE Rule to Exclude the Hypothesis of an Acute Coronary Syndrome Without Bioassay - ICARE

Condition:   Chest Pain
Intervention:   Other: CARE Rule
Sponsor:   University Hospital, Angers
Not yet recruiting - verified June 2016

APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF

Conditions:   Acute Coronary Syndrome;   Atrial Fibrillation;   Coronary Artery Disease
Interventions:   Other: Dual Therapy;   Other: Triple Therapy
Sponsors:   Klinikum der Universitaet Muenchen;   Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK);   Technische Universität München;   Helmholtz Zentrum München;   University of Göttingen;   University of München;   University Medicine Greifswald
Not yet recruiting - verified May 2016

NT-proBNP in the Management of Discharged Patients With Acutely Decompensated Heart Failure and Preserved Ejection Fraction

Conditions:   Heart Failure;   Preserved Left Ventricular Ejection Fraction
Intervention:   Other: NT-proBNP (Cardiac Biomarkers)
Sponsors:   Hospital Universitario Virgen de la Arrixaca;   Juan Cinca Cuscullola;   Pablo García Pavía;   Manuel Martinez Selles;   Antoni Bayés Genís;   Alfonso Varela Román;   Pedro Luis Sánchez Fernández
Recruiting - verified June 2016

Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study

Conditions:   Severe and Symptomatic Aortic Stenosis;   Stable Coronary Disease
Intervention:   Procedure: TAVI procedure
Sponsor:   University Hospital, Montpellier
Not yet recruiting - verified June 2016

Evaluation of hsTnI in the Management of Patients With Chest Pain in the Emergency Department

Condition:   Chest Pain
Intervention:   Other: blood taking
Sponsors:   National Heart Centre Singapore;   Singapore General Hospital;   Beckman Coulter GmbH;   Abbott
Recruiting - verified May 2016

Biventricular Pacing in Children After Surgery for Congenital Heart Disease

Condition:   Congenital Heart Disease (CHD)
Intervention:   Other: Biventricular pacing
Sponsor:   The Hospital for Sick Children
Completed - verified June 2016

Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients

Conditions:   Acute Coronary Syndromes;   ST Elevation Myocardial Infarction
Interventions:   Drug: Chewing Ticagrelor;   Drug: Oral Ticagrelor
Sponsor:   Sheba Medical Center
Recruiting - verified April 2016

Assessing the Efficacy of CardiOGoniometry (CGM) to Localise the Culprit Vessel in Mixed Vessel Disease Non-ST elevatIon Myocardial infarcTION (NSTEMI)

Condition:   Acute Coronary Syndrome
Interventions:   Device: Cardiogoniometry;   Device: 12-lead ECG
Sponsor:   Hull and East Yorkshire Hospitals NHS Trust
Recruiting - verified February 2016

A Randomised Controlled Trial of High-Flow Nasal Oxygen Versus Standard Oxygen Therapy in Critically Ill Immunocompromised Patients

Condition:   Acute Respiratory Failure
Interventions:   Procedure: standard oxygen;   Procedure: HFNO
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified June 2016

Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Condition:   Coronary Artery Disease
Interventions:   Procedure: PRU guided CABG;   Procedure: CABG per standard of care;   Device: VerifyNow assay;   Drug: Ticagrelor
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified June 2016

Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   Radiometer Medical ApS
Recruiting - verified June 2016

"Me and My Heart" Study

Condition:   Acute Coronary Syndrome
Interventions:   Device: Active group with MEMS;   Device: Active group without MEMS;   Device: Control group with MEMS;   Device: Control group without MEMS
Sponsor:   AstraZeneca
Recruiting - verified June 2016

Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)

Condition:   Cardiovascular Diseases
Interventions:   Drug: Ticagrelor;   Drug: Prasugrel;   Drug: Clopidogrel
Sponsors:   Erasmus Medical Center;   Covance
Recruiting - verified March 2016

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

Conditions:   Arterial Occlusive Diseases;   Coronary Artery Disease;   Coronary Disease;   Arteriosclerosis;   Heart Diseases;   Myocardial Ischemia;   Vascular Diseases;   Acute Coronary Syndrome
Interventions:   Drug: PZ-128;   Drug: Placebo
Sponsors:   Tufts Medical Center;   National Heart, Lung, and Blood Institute (NHLBI);   RTI International;   Inova Fairfax Hospital;   University of Massachusetts, Worcester
Recruiting - verified June 2016

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Condition:   Acute Coronary Syndrome
Interventions:   Drug: dalcetrapib;   Drug: Placebo
Sponsors:   DalCor Pharmaceuticals;   The Montreal Health Innovations Coordinating Center (MHICC);   Medpace, Inc.;   Roche Molecular Systems, Inc
Recruiting - verified June 2016

Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome

Conditions:   Diabetes Mellitus;   Acute Coronary Syndrome;   Coronary Artery Disease
Interventions:   Drug: Novel strategy Aspirin;   Drug: Conventional strategy Aspirin
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Bayer
Recruiting - verified June 2016

Reevaluation Of Systemic Early Neuromuscular Blockade

Condition:   Acute Respiratory Distress Syndrome
Intervention:   Drug: cisastracurium besylate
Sponsors:   Massachusetts General Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified May 2016

An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified June 2016

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Exenatide;   Other: Remote Ischemic Conditioning (RIC);   Drug: Placebo
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified March 2016

Frailty in Elderly Patients Receiving Cardiac Interventional Procedures

Condition:   Aged
Intervention:   Other: frailty evaluation
Sponsor:   University Hospital of Ferrara
Recruiting - verified March 2016

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Recruiting - verified June 2016

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified June 2016

Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   Instituto Mexicano del Seguro Social
Recruiting - verified June 2016

PPV to Guide Fluid Management in the PICU

Conditions:   Sepsis;   Systemic Inflammatory Response Syndrome
Intervention:   Device: Automated Pulse Pressure Variation
Sponsor:   University of North Carolina, Chapel Hill
Completed - verified June 2016

Phase I/II Trial of Early Infusion of Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Conditions:   Chronic Lymphocytic Leukemia;   CML (Chronic Myelogenous Leukemia);   MDS (Myelodysplastic Syndrome);   Acute Lymphoblastic Leukemia;   AML (Acute Myelogenous Leukemia)
Intervention:   Biological: MVST
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Suspended - verified June 2016

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

Condition:   Sickle Cell Disease
Intervention:   Drug: Hydroxyurea
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation - verified June 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified June 2016

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Intervention:   Biological: CM-CS1 T-cell infusion
Sponsors:   Celdara Medical, LLC;   Dana-Farber Cancer Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily;   Drug: Standard therapy
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Completed - verified June 2016

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Conditions:   Acute Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse;   Hodgkin's Lymphoma
Interventions:   Drug: Tacrolimus (ARM with Methotrexate);   Drug: Tacrolimus (ARM with MMF and Cyclophosphamide);   Drug: Methotrexate (ARM with Maraviroc);   Drug: Methotrexate (ARM with Bortezomib);   Drug: Maraviroc;   Drug: Bortezomib;   Drug: Mycophenolate mofetil;   Drug: Cyclophosphamide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Active, not recruiting - verified June 2016

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

Conditions:   Coronary Arteriosclerosis;   Non ST Segment Elevation Acute Coronary Syndrome
Interventions:   Device: OrbusNeich Combo stent™;   Device: Everolimus Eluting Stent (EES)
Sponsors:   OrbusNeich;   OrbusNeich Medical K.K.;   Duke Clinical Research Institute
Active, not recruiting - verified June 2016

Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Troponin
Intervention:  
Sponsors:   Minneapolis Medical Research Foundation;   Abbott Diagnostics Division;   Hennepin County Medical Center, Minneapolis
Active, not recruiting - verified June 2016

APRV/BIPAP With Spontaneous Breathing on Lung Protection

Conditions:   Respiratory Insufficiency;   Ventilator-Induced Lung Injury
Intervention:   Other: Pressure targeted modes
Sponsors:   St. Michael's Hospital, Toronto;   University of Toronto
Recruiting - verified June 2016

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Conditions:   Rivaroxaban;   Cancer-associated Thrombosis;   Recurrence;   Bleeding
Intervention:   Drug: Rivaroxaban
Sponsors:   Seoul National University Hospital;   Korean Society of Hematology Thrombosis Working Party
Active, not recruiting - verified June 2016

Acute Coronary Syndrome Genetic Study

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsors:   Peking University First Hospital;   Ministry of Science and Technology of the People´s Republic of China
Recruiting - verified June 2016

Treosulfan, Fludarabine Phosphate, and Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Conditions:   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation;   Drug: Treosulfan
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Condition:   Coronary Artery Disease (CAD)
Interventions:   Drug: Ticagrelor;   Drug: Acetylsalicylic Acid;   Drug: Clopidogrel
Sponsors:   ECRI bv;   Biosensors International;   AstraZeneca;   The Medicines Company
Active, not recruiting - verified April 2016

Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

Conditions:   Coronary Artery Disease;   Stable Angina;   Acute Coronary Syndrome
Interventions:   Drug: Ticagrelor;   Drug: Aspirin;   Drug: Placebo - Ticagrelor;   Drug: Placebo - Aspirin
Sponsors:   Deutsches Herzzentrum Muenchen;   AstraZeneca
Recruiting - verified June 2016

Tailored Antiplatelet Therapy Following PCI

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Stenosis
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor;   Genetic: Retrospective Genotype testing;   Genetic: Prospective Genotype testing
Sponsors:   Mayo Clinic;   Spartan Bioscience Inc.;   Applied Health Research Centre;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2016

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

Conditions:   Acute Myeloid Leukemia;   Acute Lymphoid Leukemia;   Hematopoetic Myelodysplasia;   Leukemia, Myelogenous, Chronic;   Lymphoma, Non-Hodgkin
Intervention:   Drug: Sitagliptin
Sponsors:   Sherif S. Farag;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

Tryptase and Coronary Heart Disease

Conditions:   Acute Coronary Syndrome With ST Elevation on Electrocardiogram;   Acute Coronary Syndrome Without ST Elevation on Electrocardiogram;   Noncritical Coronary Artery Disease With Coronary Stenosis <50%;   Aortic Aneurysms
Intervention:  
Sponsor:   Niguarda Hospital
Recruiting - verified June 2016

Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers

Condition:   Ovarian Hyperstimulation Syndrome
Interventions:   Drug: Cabergoline;   Drug: Placebo
Sponsor:   KK Women's and Children's Hospital
Active, not recruiting - verified June 2016

ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA

Condition:   Upper Gastrointestinal Bleeding
Interventions:   Drug: Rabeprazole;   Drug: Famotidine
Sponsor:   Chinese University of Hong Kong
Active, not recruiting - verified June 2016

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

Conditions:   Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions:   Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)

Condition:   Coronary Artery Disease
Interventions:   Procedure: Cypher, xience, Endeavor, Taxus;   Drug: optimal medical therapy
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Recruiting - verified June 2016

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

Conditions:   MDS;   Immunodeficiency;   GATA2
Interventions:   Drug: Cyclophosphamide (CTX, Cytoxan);   Drug: Fludarabine(Fludara,Berlex Laboratories);   Procedure: Total Body Irradiation (TBI);   Procedure: Allogeneic HSC;   Drug: Equine Anti-Thymocyte Globulin
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified June 2016

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
Interventions:   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified May 2016

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2016

Prehospital CPAP vs. Usual Care for Acute Respiratory Failure

Conditions:   Respiratory Insufficiency;   Hypoxia
Intervention:   Device: Continuous positive airway pressure ventilation mask
Sponsors:   Dalhousie University;   Nova Scotia Health Authority
Completed - verified June 2016

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2016

ARDS - Clinical Epidemiology and the Role of the Inflammatory Response - SCOR in Acute Lung Injury

Conditions:   Acute Respiratory Distress Syndrome;   Lung Diseases
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified June 2016